

Bari Talente, JD

Executive Vice President, Advocacy
National Multiple Sclerosis Society



@BTalente

Looking Forward: A Value-Based Approach to Drug Pricing



What is MS?

Chronic, often
disabling disease


Diagnosis between
ages 20-50

Most people
diagnosed with
relapsing forms of MS

Early and ongoing treatment
is the best way to slow
disease progression and
prevent accumulation of
disability

MS Disease Modifying Treatments

Hartung, DM- PharmD, MPH; Oregon State University/Oregon Health and Science University



What Should be Considered When Assessing Value?

- To get societal/system value, people need to take their medications
- We have to think about the end user
- Incorporate patient-centered factors into assessing value
- What is important to a patient?
 - What do patients want from a treatment?
 - What do they need to adhere to a treatment regiment?

More similarities than differences

So What Matters to Patients?

Table 3. The Patient Perspective on Important Factors when Choosing a DMT

Decision-making factor	Important / Very Important
Delay disability	94%
Prevent relapse / new MRI lesions	94%
Continue working / normal activities	90%
Provider recommends therapy	86%
Other long term risks	71%
Health plan restrictions	69%
Risk of PML	68%
Out-of-pocket costs	66%
Route of administration	61%
Dosing frequency	58%
Risk of side effects	55%
Monitoring / blood tests	44%

Additional Considerations

- Value for multiple products in a single mechanism of action
 - Side effect/safety/monitoring may look different
 - Is the R&D investment the same as the first in class product?
- What is innovation?
- Paying for different dosing schedules
 - Gene therapies
 - Semi-annual doses
 - One week/month a year